The Nellcor device can be used to monitor adults and babies at risk for respiratory distress and to help screen infants for critical congenital heart disease.
"Covidien’s new generation of portable monitors is easy to use and brings our proven pulse oximetry technology to patients inside the hospital, in healthcare facilities, and even in their own homes," said Matt Anderson, vice president & general manager of patient monitoring. "Because our pulse oximetry technology relies on cardiac signals, it mitigates signal interference, offering caregivers peace of mind."
Covidien has been actively seeking to move further into the home healthcare space. Last month, the Mansfield, Mass.-based company licensed its ZephyrLIFE remote monitoring platform to healthcare solutions concern Geneia.
Covidien’s line of oximetry products were among the best performing in its U.S. market portfolio during the second quarter, according to CEO Jose Almeida.